
Pealiquitech™ Technology
At the heart of this innovation is Alyval’s patented pealiquitech™ technology, featuring PEA (palmitoylethanolamide). PEA is a naturally occurring molecule produced by the body and known for its anti-inflammatory, soothing, antimicrobial, and neuroprotective properties. However, due to its poor solubility, PEA is typically difficult for the skin to absorb.
Due to its low solubility, PEA can be difficult to deliver effectively in topical formulations. The pealiquitech™ system uses a proprietary solubilisation process to help maintain PEA in a stable, active and bioavailable form, supporting controlled release and effective delivery to the skin.
Other added ingredients include hyaluronic acid, argireline and vitamin B12.
In Vivo Tests
Randomised, double-blind gynaecological clinical study conducted at Vittore Buzzi Hospital, Milan on 40 women with vestibulodynia, a condition often presenting as burning, stinging, or discomfort on contact with the vestibular area. The aim was to evaluate the cosmetic efficacy of Alyval MED after 2 months of daily application.
The study showed that the use of Alyval MED was associated with a 45% reduction in perceived discomfort during common contact situations, compared with the placebo group.

The skin appeared calmer and less reactive following treatment. Current Perception Threshold (CPT) testing using a Neurometer at 2000 Hz, 250 Hz and 5 Hz demonstrated an approximately 19% increase in perceptual threshold in the Alyval MED treatment group, indicating reduced sensitisation of vestibular nerve fibres.










